Juul Faces Market Withdrawal in the US: Implications and Controversies

Jul.08.2022
Juul Faces Market Withdrawal in the US: Implications and Controversies
The FDA ordered Juul products to be removed from the US market due to concerns over youth vaping.

On June 23, the US Food and Drug Administration (FDA) announced that all Juul products must be removed from the US market. This decision significantly expanded the existing ban on the company's nicotine e-cigarettes among teenagers to include adults as well. The following day, Juul appealed to the federal court to temporarily halt the ban and questioned the decision. The court agreed to temporarily suspend the ban, and currently, Juul products are still being sold in the US.


Lynn Kozlowski, a professor at the State University of New York at Buffalo's School of Public Health and Health Professions, has been researching nicotine and tobacco addiction for several decades. In this Q&A, he addresses the recent controversy surrounding Juul products and how they fit into broader discussions among adults and young people about e-cigarettes, tobacco use, and public health.


Why does the US Food and Drug Administration want to stop the sale of Juul products?


According to the FDA, the decision to remove certain flavored electronic cigarette products from the market is a preventative measure due to the lack of "sufficient evidence of product toxicology profiles" to ensure public health and safety. The FDA also noted that it has not received any information indicating that Juul products pose an imminent danger.


In a statement, FDA Commissioner Robert M. Califf addressed the impact of Juul products on youth e-cigarette use. This decision comes as some are hoping for new bans on Juul products and other adult e-cigarettes, in effort to decrease teen e-cigarette usage.


How do the health risks of electronic cigarettes compare to traditional smoking?


At least half of smokers die prematurely due to cancer, obstructive lung disease and cardiovascular diseases caused by smoking, which shorten their average lifespan by 10 years.


Currently, there is a lack of long-term epidemiological data on e-cigarettes. However, assessments conducted in the United States and the United Kingdom have concluded that while the harm from e-cigarettes may be much less than that of traditional cigarettes, they still pose some risks. Potential hazards include nicotine addiction and some cardiovascular risks, although it is estimated that these risks are lower than those associated with smoking cigarettes.


Can electronic cigarettes reduce the harm caused by traditional smoking?


I do not encourage anyone to vape if they do not need to. However, if someone smokes and e-cigarettes help them quit completely, they can be a useful tool in reducing smoking and health issues. Quitting smoking is indisputably good for your health. Research shows that if someone quits smoking before the age of 40, they can avoid 90% of their risk of death compared to continuing to smoke. If someone quits smoking before the age of 30, their health risks are almost the same as someone who has never smoked.


The Centers for Disease Control and Prevention states that there is limited evidence to suggest that e-cigarettes aid in smoking cessation. The U.S. Food and Drug Administration has approved some e-cigarettes for sale, noting that they can be a beneficial tool for smokers in significantly reducing their tobacco use or quitting altogether.


Recent research has shown that electronic cigarettes are more effective in aiding smokers to quit than nicotine replacement therapy. The UK National Health Service has approved electronic cigarettes as a recognized form of smoking cessation aid.


Is vaping still popular among teenagers as it was before?


Teen e-cigarette use is on the decline, according to data from the Centers for Disease Control and Prevention. In 2019, 27.5 percent of high school students reported having used e-cigarettes within the past month. That number dropped to 19.6 percent by 2020, and again to 11.3 percent by 2022. Just over a quarter of monthly users, or roughly 3 percent of high schoolers in 2022, reported using e-cigarettes daily.


Some of the reduction may be due to COVID-19, restrictions on young people's access, and government anti-vaping campaigns.


The widespread publicity around the serious respiratory illness caused by e-cigarettes, known as EVALI, is likely to deter many people from using them. However, research has ultimately shown that the illness is primarily caused by illicit THC-containing e-cigarette products sold on the black market.


Will teenagers who vape lead to a higher smoking rate among adolescents?


Although the decrease in teen e-cigarette use is encouraging, an important question worth asking is whether e-cigarettes directly lead to smoking later on.


Parents have valid reasons to be concerned that e-cigarettes may serve as a gateway to smoking. However, research does not necessarily support this strong causal relationship. Despite the recent surge in e-cigarette use across the country, smoking rates have actually decreased.


According to data from a national survey of nearly 40,000 participants in the US over the past few years, researchers have found that less than 1% of those who tried e-cigarettes for the first time became long-term smokers. Compared to those who first tried cigarettes or other tobacco products, people who first tried e-cigarettes were also less likely to become smokers.


Another large-scale study on American youth found that once researchers controlled for general risky behavior, the history of using e-cigarettes was only moderately or insignificantly associated with increased smoking rates.


How do you balance adult usage with teenage safety?


Even though e-cigarettes are not a major factor contributing to youth smoking, the use of e-cigarette products by young people is still a cause for concern, despite the ban on selling e-cigarettes to those under the age of 21 in 2019.


Completely banning products that may be helpful for adult smokers who want to quit is not the only way to reduce young people's access to these services. As an example, a proposal suggests moving the sales of all nicotine and tobacco products to stores that only allow entry for individuals of 21 years or older.


While products like Juul deserve research and regulation, it is important to remember the established deadline for verification and the ease of access for cigarettes - whether it is for adults or the many teenagers who start smoking every year and will become adult smokers. Persuading as many smokers to quit as possible will save lives.


This article contains excerpts or reprints from third-party sources, and the copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any unit or individual who needs to reprint must contact the author, and direct reprinting is prohibited.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Japan Tobacco Inc. (JT) launched three limited-edition autumn tobacco sticks for its Ploom heated tobacco devices in Japan on October 16, 2026, under the EVO, MEVIUS and CAMEL brands. All three are regular tobacco variants with seasonal packaging. Each pack contains 20 sticks, priced at ¥620, ¥590 and ¥570, respectively, including tax. The products are compatible with all Ploom devices and are sold in limited quantities exclusively through the CLUB JT online store while supplies last.
product
Oct.20
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23